Ruben Raychaudhuri, MD

Physician, Fred Hutch, Assistant Professor, Clinical Research Division, Fred Hutch, Assistant Professor, Division of Hematology and Oncology, University of Washington School of Medicine

Articles by Ruben Raychaudhuri, MD

Oncology Unplugged With Dr Chandler Park

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

ByChandler Park, MD, MSc, FACP,Petros Grivas MD, PhD,Ruben Raychaudhuri, MD

February 26th 2025

Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.

Latest Updated Articles

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD
February 26th 2025

Ruben Raychaudhuri, MD

Articles by Ruben Raychaudhuri, MD

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

Latest Updated Articles

Trending on OncLive

FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer

FDA Flashback: Breast Cancer Decisions and News From July 2026

FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

Dostarlimab Monotherapy Elicits Responses in First-Line PD-L1-Positive HNSCC

Dr Brufsky on the FDA Approval of Gedatolisib Plus Fulvestrant ± Palbociclib in PIK3CA Wild-Type Breast Cancer